APA (7th ed.) Citation

Pegoraro, S., Duffey, M., Otto, T., Wang, Y., Rösemann, R., Baumgartner, R., . . . Lanzer, M. (2017). SC83288 is a clinical development candidate for the treatment of severe malaria. Nature Communications, 8, . https://doi.org/10.1038/ncomms14193

Chicago Style (17th ed.) Citation

Pegoraro, Stefano, Maëlle Duffey, Thomas Otto, Yulin Wang, Roman Rösemann, Roland Baumgartner, Stefanie Katrin Fehler, Cecilia P. Sanchez, and Michael Lanzer. "SC83288 Is a Clinical Development Candidate for the Treatment of Severe Malaria." Nature Communications 8 (2017). https://doi.org/10.1038/ncomms14193.

MLA (9th ed.) Citation

Pegoraro, Stefano, et al. "SC83288 Is a Clinical Development Candidate for the Treatment of Severe Malaria." Nature Communications, vol. 8, 2017, https://doi.org/10.1038/ncomms14193.